Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bioo Scientific First to Address Small RNA-Seq Bias Concerns

Published: Wednesday, August 13, 2014
Last Updated: Wednesday, August 13, 2014
Bookmark and Share
Company launches NEXTflex™ Small RNA Sequencing Kit v2.

Bioo Scientific has launched the patent pending NEXTflex™ Small RNA Sequencing Kit v2, which utilizes randomized adapters to significantly reduce ligation bias from library preparation, resulting in the most accurate data available, as illustrated in a number of published papers.

The NEXTflex Small RNA Sequencing Kit v2 provides an easy, flexible, cost-effective solution for generating small RNA libraries for sequencing on Illumina sequencing platforms.

Traditional small RNA sequencing introduces bias at the ligation step, because no single adapter sequence is able to efficiently ligate to all small RNAs.

The NEXTflex Small RNA-Seq Library Prep Kit v2 overcomes this bias using randomized sequences at the ligation site. This randomized adapter strategy allows small RNAs of any sequence to “find” their respective optimal adapter, resulting in small RNA libraries with a dramatic reduction in bias.

The NEXTflex Small RNA Sequencing Kit v2 allows users to generate libraries directly from isolated small RNAs, microRNAs or total RNA. The protocol is designed to significantly reduce adapter dimer formation using an adapter depletion solution. Barcoded primers, added during PCR, are available separately, allowing up to 48 samples to be multiplexed.

According to Dr. Masoud Toloue, VP, Genomic Research, “One of Bioo Scientific’s primary focuses is the reduction of biases associated with next generation sequencing. The incorporation of randomized adapters is the latest innovative technology we’ve put into practice that allows for the most accurate sequencing-based measurement of small RNAs.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bioo Scientific Partners with the Icahn School of Medicine at Mount Sinai
Partnership to reduce ligation bias in next generation sequencing.
Saturday, February 14, 2015
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
The funding allows Bioo Scientific to develop a quantitative technology to measure miRNA expression in living cells or tumor tissue.
Wednesday, December 08, 2010
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
Bioo Scientific announced today that it has been awarded a grant of $150,000 from the National Science Foundation to support its research for the biomolecular detection of microRNA.
Wednesday, December 08, 2010
Bioo Scientific Chooses Eureka Genomics as its Next-Generation Sequencing Provider
Bioo Scientific chose Eureka Genomics based on their extensive sequencing experience, quick turnaround times and strong bioinformatics support.
Thursday, August 19, 2010
NSF Funds Research Partnership Between Bioo Scientific and Mirna Therapeutics
The funding will support tumor regression and pharmacokinetic studies on targeted delivery of microRNAs.
Thursday, July 22, 2010
Small RNA Barcoding for Sample Multiplexing
AIR Barcoded Adapters, designed to work with Illumina Next-Generation Sequencers, provide flexibility in high-throughput sequencing applications.
Monday, January 25, 2010
Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi
Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells.
Tuesday, November 17, 2009
Bioo Scientific Launches a New Division, Bioo Therapeutics
Bioo Therapeutics will leverage Bioo Scientific’s proprietary drug delivery vehicles and antibody research expertise to develop therapeutic agents.
Thursday, November 12, 2009
Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi In Vivo Delivery Technology
A $500,000 Phase II grant will help to develop kits and reagents based on the patent-pending Targeted Transport Technology.
Wednesday, July 29, 2009
BIOO Scientific Corp. Receives Two Grants from US Agencies
Company receives NIH grant for improving antibody technology and launches a set of novel products for directed in vivo delivery of SiRNA.
Friday, January 04, 2008
Custom RNA Interference Service
BIOO Scientific is launching a service to perform in vivo RNAi testing to facilitate progress in the drug pipeline.
Thursday, April 12, 2007
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos